new SEDAR filing clarifying insider ownershipDr Arkady Mandel – Interim Chief Executive Officer and Chief Scientific Officer and
Director – Immediately prior to the closing of the Offering, Dr. Mandel held the following
securities: 60,000 Common Shares (representing less than 1% of the currently issued and
outstanding Common Shares), (ii) Nil Warrants, and (iii) 1,500,000 Stock Options.
Assuming full conversion of the Warrants and Stock Options, Dr. Mandel would have held,
in aggregate, 1,560,000 Common Shares representing less than 1% of the then issued and
outstanding Common Shares (calculated on a partially diluted basis, assuming no
convertible securities other than those held by the insider are converted or exercised). Following the closing of the Offering, Dr. Mandel holds the following securities: (i)
Kristina Hachey – Chief Financial Officer and Director – Immediately prior to the closing
of the Offering, Ms. Hachey held the following securities: 2,006,267 Common Shares
(representing 1.4% of the currently issued and outstanding Common Shares), (ii) 302,857
Warrants, and (iii) 1,500,000 Stock Options. Assuming full conversion of the Warrants and
Stock Options, Ms. Hachey would have held, in aggregate, 3,809,124 Common Shares
representing 1.3% of the then issued and outstanding Common Shares (calculated on a
partially diluted basis, assuming no convertible securities other than those held by the
insider are converted or exercised). Following the closing of the Offering, Ms. Hachey
holds the following securities: (i) 3,006,267 Common Shares (representing 1.4% of the
currently issued and outstanding Common Shares), (ii) 1,302,857 Warrants, and (iii)
1,500,000 Stock Options. Assuming full conversion of all convertible securities held, Ms.
Hachey would hold an aggregate of 5,809,124 Common Shares, representing 1.9% of the
then issued and outstanding Common Shares (calculated on a fully diluted basis, assuming
all convertible securities held are converted or exercised
Roger Dumoulin-White – Director of Business Development – Immediately prior to the
closing of the Offering, Mr. Dumoulin-White held or exercised direction or control over
the following securities: (i) 8,521,053 Common Shares (representing 4.1% of the currently
issued and outstanding Common Shares), (ii) 795,714 Warrants, and (iii) 2,500,000
Common Shares (“Stock Options”). Assuming full conversion of the Warrants and Stock
Options, Mr. Dumoulin-White would have held or exercised direction or control over, in
aggregate, 11,816,767 Common Shares representing 5.7% of the then issued and
outstanding Common Shares (calculated on a partially diluted basis, assuming no
convertible securities other than those held by the insider are converted or exercised).
Following the closing of the Offering, Mr. Dumoulin-White holds or exercises direction or
control over the following securities: (i) 9,821,053 Common Shares (representing 4.6% of
the currently issued and outstanding Common Shares), (ii) 2,095,714 Warrants, and (iii)
2,500,000 Stock Options. Assuming full conversion of all convertible securities held, Mr.
Dumoulin-White would hold an aggregate of 14,416,767 Common Shares, representing
4.8% of the then issued and outstanding Common Shares (calculated on a fully diluted
basis, assuming all convertible securities held are converted or exercised). Please note that
the numbers stated above include an aggregate of 444,666 common shares and 350,000
warrants which are beneficially held by his children
KH + RDW = 20m shares assuming full conversion
160,000 Common Shares (representing less than 1% of the currently issued and outstanding
Common Shares), (ii) 100,000 Warrants, and (iii) 1,500,000 Stock Options. Assuming full
conversion of all convertible securities held, Dr. Mandel would hold an aggregate of
1,760,000 Common Shares, representing less than 1% of the then issued and outstanding
Common Shares (calculated on a fully diluted basis, assuming all convertible securities
held are converted or exercised)